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A B S T R A C T
Background
Cellular localization of severe acute respiratory syndrome coronavirus (SARS-CoV) in the
lungs of patients with SARS is important in confirming the etiological association of the virus
with disease as well as in understanding the pathogenesis of the disease. To our knowledge,
there have been no comprehensive studies investigating viral infection at the cellular level in
humans.
Methods and Findings
We collected the largest series of fatal cases of SARS with autopsy material to date by
merging the pathological material from two regions involved in the 2003 worldwide SARS
outbreak in Hong Kong, China, and Toronto, Canada. We developed a monoclonal antibody
against the SARS-CoV nucleoprotein and used it together with in situ hybridization (ISH) to
analyze the autopsy lung tissues of 32 patients with SARS from Hong Kong and Toronto. We
compared the results of these assays with the pulmonary pathologies and the clinical course of
illness for each patient. SARS-CoV nucleoprotein and RNA were detected by immunohis-
tochemistry and ISH, respectively, primarily in alveolar pneumocytes and, less frequently, in
macrophages. Such localization was detected in four of the seven patients who died within two
weeks of illness onset, and in none of the 25 patients who died later than two weeks after
symptom onset.
Conclusions
The pulmonary alveolar epithelium is the chief target of SARS-CoV, with macrophages
infected subsequently. Viral replication appears to be limited to the first two weeks after
symptom onset, with little evidence of continued widespread replication after this period. If
antiviral therapy is considered for future treatment, it should be focused on this two-week
period of acute clinical disease.
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Introduction
Severe acute respiratory syndrome (SARS) is a new disease
that originated in the Guangdong province of China in
November 2002, and subsequently spread to Hong Kong in
February 2003 [1,2]. Facilitated by busy international traffic,
it soon caused major disease outbreaks in multiple cities
around the world over the following five months [3,4]. It had
an alarming tendency to spread to health care workers, and
unlike most respiratory viral infections, predominantly
involved the lower respiratory tract. The disease was
associated with an unusually high morbidity and mortality;
20%–30% of patients developed severe respiratory symptoms
requiring intensive care support [2,3,5]. Worldwide, the
average case mortality rate was 10.0%, but in Hong Kong
and Toronto, the case mortality rate was 17.0%, with older
patients and those with chronic illnesses having a worse
outcome [1,2,5].
The causative agent has now been determined to be a novel
coronavirus (SARS-CoV) that is genetically distinct from any
previously identified coronavirus known to cause disease in
animals or humans [1,6–8]. In a primate model system,
experimental infection of cynomolgus macaques with SARS-
CoV alone was sufficient to cause a disease complex similar to
that observed in humans [9,10]. Genetically, the coronavirus
species closest to SARS-CoV are those isolated from small
animals traded for culinary purposes, such as the Himalayan
palm civet and raccoon-dog, which show 99.8% sequence
homology but differ by the insertion of a 29-nucleotide
fragment [11]. It is postulated that both coronaviruses have
probably arisen from a common natural reservoir, with
facilitated interspecies transmission and possibly genetic
alteration to SARS-CoV during the close handling and
trading of the animals in the same environment.
The pulmonary pathology observed in limited postmortem
material has been reported together with the clinical
symptomatology of SARS [2,8,12–15]. The detection of the
coronavirus in relation to pulmonary changes is a critical
factor in the understanding of the pathogenesis of the
disease. However, this has been hampered by the lack of
readily available monoclonal anti-SARS antibodies, as well as
the impracticability of extensive electron microscopic exami-
nation. Furthermore, although investigation of the time
course of SARS-CoV infection with respect to the detection
of SARS-CoV RNA has been done by PCR methods, there
have been no systematic, large-scale investigations of the
temporal or cellular detection of SARS-CoV in lung tissues.
Additionally, the extent of organ distribution has not been
examined in great detail. Indeed, a recent single-case
publication on the immunohistochemical detection of SARS
highlighted ‘‘. . .the need for more cases of SARS to be studied
to determine the temporal relationship between the duration
of illness and viral clearance in human lung tissue. . .’’ [15].
This study therefore had three purposes. The first was to
investigate the presence of SARS-CoV by immunohistochem-
istry (IHC) and in situ hybridization (ISH) in lung autopsy
specimens from patients who died at different time points of
the disease. The second purpose was to determine the cellular
distribution of SARS within the lung, and the third was to
examine extrapulmonary tissues of patients who died of
SARS to determine the extent of systemic distribution.
Methods
Patient Profiles and Material
A total of 32 patients who died with SARS-CoV infection
confirmed by PCR, serological, or viral culture tests were
included in the study. The patients came from two geo-
graphical regions affected by SARS (Hong Kong [HK] and
Toronto, Canada [TO]). For HK cases 1 and 10–13, whole lung
specimens were perfused at autopsy with 4% neutral buffered
formalin at 20–30 cm H2O pressure until the lungs were fully
expanded, before immersion in formalin fixative. Multiple
blocks were extensively sampled from all lobes of the lungs
for HK cases 1, 6, 7, and 9–13; limited representative blocks
were sampled from HK cases 2–5 and 8. For all Toronto cases,
approximately half of each lung lobe was removed at autopsy,
and a portion was snap-frozen for molecular studies. Multiple
blocks of tissue were processed from each lobe for light
microscopic examination. Stains for microorganisms and for
collagen, and immunohistochemical stains for microorgan-
isms, were performed as necessary. The clinical profiles were
retrieved from the patients’ records. HK case 1 was a patient
who died in the quarantine period for SARS exposure during
hospitalization for congestive heart failure. PCR of a throat
swab was positive on the fifth day after symptom onset, and
she developed fever and respiratory symptoms thereafter. HK
case 13 was a patient who died unexpectedly during
convalescence from SARS. All other patients died of SARS
with progressive deterioration in lung function. All HK
patients except cases 1 and 13 had received ventilatory
support during life. The pulmonary histopathological fea-
tures of six of the HK cases (2–6 and 8) have been previously
reported [12]. In addition to the autopsy tissue from all HK
cases, HK case 5 also had an open lung biopsy, which was also
included in this study. Descriptions of the procurement and
clinical courses of the TO cases have been described in
previous reports [14,16].
Development of a Monoclonal Antibody against SARS-
CoV Nucleoprotein
BALB/c mice were immunized intraperitoneally with 0.1 ml
of heat-killed SARS-CoV HKU39849-infected FRhK4 cell
lysate (107 TCID50/ml). Injections of similar doses were
repeated biweekly for 2 mo. Four days after the last booster,
108 spleen cells from an immunized mouse were fused with
107 of NSI myeloma cells with polyethylene glycol (PEG,
molecular weight 4,000; BDH, Poole, United Kingdom) as the
fusing agent. Hybridomas were screened for production of
antibodies against SARS-CoV HKU39849-infected cells and
recombinant SARS-CoV nucleocapsid protein by ELISA.
Those that produced SARS-CoV nucleoprotein-specific anti-
bodies were cloned twice by limiting dilution. Purified
hybridomas were then injected intraperitoneally into mineral
oil-primed mice for the production of ascitic fluid. Mono-
clonal antibodies (4D11 and 3E4) were purified from the
ascitic fluid by precipitation with 50% ammonium sulfate
and subcloned to ensure monoclonality.
Development of Transfection Controls
The open reading frames of spike (S), envelope (E), and N
genes of SARS-CoV were cloned into the AgeI site of a
protein expression vector, pcDNA3A [17]. To express the
above viral proteins in eukaryotic cells, these protein
expression plasmids were transfected into 293T cells individ-
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ually or in appropriate combinations. Briefly, 1 lg of each of
the plasmids was transfected into 293T cells by Lipofectamine
2000 (Invitrogen, Carlsbad, California, United States) as
instructed by the manufacturer. At the indicated posttrans-
fection time points, transfected cells were harvested and
washed with PBS, then centrifuged at 1,600 rpm for 10 min.
Pelleted cells were fixed in PBS with 0.1% glutaraldehyde and
2% formaldehyde, and stored at 4 8C. SARS-CoV S and E
gene-transfected cells were used as negative controls, and
SARS-CoV N gene-transfected cells were used as positive
controls for IHC to confirm the specificity of the monoclonal
antibodies against SARS-CoV nucleoprotein.
Immunohistochemistry
The primary antibodies used included those against
cytokeratin (1:50, clone AE1/AE3 [Dako, Glostrup, Denmark]),
CD68 (1:50; clone KP1, Dako), EMA (clone E29, Dako), thyroid
transcription factor 1 (TTF1; clone 8G7G3/1, Zymed/Invitro-
gen), chromogranin (clone LK2H10 [Ventana, Tucson, Ari-
zona, United States]), DC-SIGN (a gift from Professor J-L
Virilizier, Pasteur Institute, Paris, France), LCA (clone T29/33,
Dako), and SARS-CoV N (as described above) (1:400, clone
4D11). Antigen retrieval was performed by microwaving
sections in 10 mM citrate buffer (pH 6.0) for 15 min and
incubating with 1:200 4D11 antibody at 4 8C overnight.
Secondary labeling was performed with biotinylated rabbit
anti-mouse (Dako #E-0354) at 1:100 for 30 min at room
temperature and was followed by incubation with streptavi-
din-ABC complex (Dako #K-0377) at 1:100 for 30 min at room
temperature and color development by the 3-amino-9-ethyl-
carbazole (AEC) substrate kit (Vector Laboratories, Burlin-
game, California, United States; #SK-4200) at room
temperature (15–30 min). For double labeling of lung tissue
sections, the 4D11 antibody was labeled with FITC, and a
TRITC anti-mouse secondary antibody was used. Sections
were microwaved in 10 mM citrate buffer (pH 6.0) for 15 min,
blocked with 10% normal donkey serum for 10 min at room
temperature, incubated with the non-SARS monoclonal
overnight, then incubated with TRITC-conjugated donkey
anti-mouse antibody at 1:100 for 1 h at room temperature.
The FITC-conjugated 4D11 antibody was incubated at 1:100
for 1 h at room temperature, followed by counterstaining of
the nuclei with DAPI for 4 min and mounting with DAKO
fluorescence mount (Dako #S-3023). Examination was per-
formed with a Nikon Eclipse E-800 fluorescent microscope
with a dual FITC/rhodamine filter.
In Situ Hybridization
We produced digoxigenin-labeled antisense riboprobes
specific for the N, E, and S genes of SARS-CoV, and these
were pooled and hybridized with 30 lg/ml proteinase K-
treated lung sections for 30 min at room temperature. The
hybridization buffer (250 lg/ml salmon sperm DNA, 125 lg/
ml rat total RNA, 200 mg/ml yeast tRNA, 50% deionized
formamide, 10% dextran sulfate, 13 Denhardt’s solution, 1
mM EDTA [pH 8.0], 0.01% sodium pyrophosphate, 0.3 M
sodium chloride, and 10 mM Tris-HCl [pH 8.0]) was mixed
with the probes and hybridized overnight at 508C. The
hybridized probes were detected with mouse anti-digoxigenin
at 1:100 in 10% normal rabbit serum for 1 h at room
temperature, then biotinylated rabbit anti-mouse (Dako, E-
0354) at 1/100 for 30 min. at room temperature, followed by
detection with AEC substrate kit (Vector, SK-4200) at room
temperature (up to 30 min). Prior to the tests, the sensitivity
of the SARS-CoV probes were verified semiquantitatively by
hybridization to separate cell block preparations of a SARS-
CoV infected FRHK4 cell line harvested at 8 and 24 h.
RT-PCR
SARS-CoV RT-PCR was completed on fresh (HK cases 1
and 10–13), fixed (HK cases 2–9), and snap-frozen (all TO
cases) lung tissues from all patients. For the HK cases, total
RNA was extracted by standard methods and reverse tran-
scribed to cDNA with reverse transcriptase. PCR was
performed with initial denaturation at 94 8C for 8 min
followed by 40 cycles of 94 8C for 1 min, 50 8C for 1 min, and
72 8C for 1 min using primers as previously described [1,5,12].
For the TO cases, RT-PCR was completed using RealArt HPA-
Coronavirus LC-RT assay (Artus, Hamburg, Germany) as
previously described [16,18].
Results
The HK and TO cases’ clinical profile, treatment history,
and SARS-CoV IHC, ISH, and RT-PCR results are summar-
ized in Table 1.
Lung Pathology
HK patient 1, who died 5 d after symptom onset during
quarantine for SARS contact, showed moderate interstitial
and alveolar edema with occasional epithelial desquamation
and regeneration. A moderate number of macrophages with
abundant foamy cytoplasm had accumulated in the alveolar
spaces, but giant cells were not observed. In addition, features
of aspiration pneumonia were present, involving small
bronchi and adjacent parenchyma in all lobes of the lung.
HK patients 2–12 showed established changes indicating
diffuse alveolar damage (DAD) at different phases of disease
progression that affected the lungs to varying extents. Lung
pathology of the TO cases has been described previously [14].
Although most of the advanced histological changes
revealing DAD can be attributed to ventilation, it should be
pointed out that there were also changes of DAD present in
five of the TO cases in which no intubation was carried out;
thus, viral damage is therefore the most likely mechanism of
these changes.
SARS-CoV IHC, ISH, and RT-PCR Results
The transfected cells showed strong cytoplasmic staining
for transfectants containing the N gene with no staining on
the M or S gene transfectants (Figure 1), confirming the
specificity of the monoclonal antibody for the N protein. The
control sections of FRhK4 cells showed cytoplasmic staining
that was focal at 8 h and diffuse at 24 h.
Four cases showed positive staining for N protein by IHC
(HK case 1 and TO cases 1, 4, and 5) (Figure 2). All four of
these cases died within 14 d of symptom onset. No staining of
the bronchial epithelium was present (Figure 2A), and there
was only focal staining of the bronchiolar epithelium (Figure
2B), which showed no evidence of necrosis or regeneration.
This observation was confirmed by electron microscopy with
viral particles identified in ciliated cells. There was cytoplas-
mic staining of flattened type 1 pneumocytes as well as
alveolar macrophages (Figure 2C and 2D). Adjacent hilar
lymph nodes were available for examination in one case (HK
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case 1), and, of six nodes sampled from this patient, only one
isolated mononuclear cell was noted that stained positive for
N protein but was negative for the N gene by ISH. Although
the staining of the pneumocytes was diffusely cytoplasmic, the
staining of the alveolar macrophages was coarsely granular
(Figure 2F). For all patients who died beyond 14 d after
symptom onset, only scattered single positive cells were seen
in lung sections (Figure 2G and 2H), and these were in
flattened pneumocytes as well as in mononuclear cells. In one
of the Toronto cases (TO case 1) a thrombus was identified
(Figure 2E), and positive elongated cells as well as rounded
mononuclear cells were identified in this thrombus. This
thrombus was present in only one section, and further
labeling to confirm the etiology of the infected cells could not
be performed. None of the multinucleated epithelial cells
seen in any of the patients were positive by ISH or IHC.
In the four cases that stained positive for N protein by IHC,
double labeling with the directly conjugated FITC SARS
monoclonal antibody and antibodies for macrophages and
epithelial cells showed that the infected cells were positive for
EMA (anti-epithelial) and CD68 (anti-macrophage) (Figure 3A
and 3B). The number of infected cells was greatest in TO case
1 and HK case 1, both of whom died 5 d after symptom onset.
Of interest, TO case 1 showed positive staining of epithelial
cells but no staining of macrophages (Figure 3C and 3D).
Macrophages showed positive coarse granular staining in HK
case 1 and TO cases 4 and 5, who died 11 and 14 d after
symptom onset, respectively (Figure 3E). No staining was seen
in chromogranin-positive or DC-SIGN-positive cells, and no
colocalization with TTF1 (a marker for type 2 pneumocytes)
was seen. No staining of lymphocytes was identified. TO case
5, who died on the day 14 after symptom onset, had only
scattered single positive cells, and these were in flattened
epithelial cells and mononuclear cells.
The same four cases that showed positive staining for N
protein by IHC (HK case 1 and TO cases 1, 4, and 5) were also
positive by ISH for the pooled S, E, and N SARS-CoV genes.
Multiple lung samples from HK case 1 showed strong
cytoplasmic signals in alveolar cells, including desquamating
pneumocytes and alveolar macrophages. Weak signals were
detected in occasional macrophages scattered along the
bronchial epithelium. No signals were detected in endothelial
or stromal cells. In addition to the four cases that stained
positive for SARS-CoV by IHN and ISH, a few SARS-CoV
infected cells were also detected by ISH and IHC in an open
lung biopsy taken 10 d after symptom onset from HK case 5;
Table 1. Profile of Cases Listed According to Duration of Disease from Symptom Onset for Each Location
Case
Locations
Case ID
Number
Sex Age Days from
Symptom
Onset to Death
RT-PCR
of Lung
IHC ISH Therapeutic Agents
Ribavirin Steroids
Hong Kong 1 F 80 5 þ þ þ N N
2 F 39 9 þ   Y Y
3 M 49 17    N N
4 M 64 18 þ   Y Y
5 M 77 20 þ   N Y
6 F 37 21    Y Y
7 M 71 24 þ   Y Y
8 M 53 25 þ   Y Y
9 M 47 27 þ   Y Y
10 M 48 30 þ   Y Y
11 M 40 36    Y Y
12 M 82 36 þ   Y Y
13 M 58 39 þ   Y Y
Canada 1 F 88 5 þ þ þ N N
2 M 62 10 þ   Y Y
3 F 67 10 þ   N Y
4 M 76 11 þ þ þ Y N
5 M 57 14 þ þ þ N Y
6 F 78 15 þ   N N
7 M 43 16 þ   Y N
8 M 78 18 þ   Y Y
9 M 63 20 þ   Y Y
10 F 78 23 þ   Y Y
11 F 73 24 þ   Y Y
12 M 45 24 þ   N Y
13 F 99 25 þ   Y N
14 F 81 27 þ   N Y
15 M 44 29 þ   Y Y
16 F 79 29 þ   N Y
17 M 68 34 þ   NA NA
18 F 51 43 þ   N Y
19 F 77 51 þ   N Y
þ, positive result; , negative result; N, no; NA, not available; Y, yes.
DOI: 10.1371/journal.pmed.0030027.t001
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however, both ISH and IHC were negative on the autopsy
lung sample taken from this patient after death (20 d after
symptom onset).
Results of RT-PCR are listed in Table 1. Autopsy lung
samples from all but three HK cases were positive for SARS-
CoV by RT-PCR. When IHC and ISH staining was compared
with RT-PCR viral load and disease duration, positive cells by
IHC and ISH were identified mainly in cases who had died
less than 14 d from onset of illness and in whom lung tissues
were associated with viral loads greater than 105 copies per
gram of tissue. In two of the cases that were positive for IHC
in the lung, other organs were examined for IHC. In HK case
1, when there was strong positive IHC and ISH staining of the
lung identified, no IHC- or ISH-positive cells were identified
in other organs examined (adrenal gland, kidney, spleen,
liver, and heart). In TO case 4, which also showed positive
lung staining, no other organs were positive by IHC or ISH
(liver, spleen, and kidney). Examination of three other TO
cases that stained negative in the lung also showed no positive
extrapulmonary staining.
Discussion
SARS-CoV nucleocapsid protein and RNA were detected in
lung autopsy samples from four of the seven patients who
died within 2 wk after illness onset, all of whom had high
(greater than 105 copies per gram) RT-PCR viral loads in the
autopsy lung tissue. SARS-CoV nucleocapsid protein and
RNA were also detected in an open lung biopsy from a
patient on day 5 after symptom onset (before death), but not
in the same patient’s autopsy lung specimen collected on day
20 after symptom onset. Among those lung samples staining
positive by ISH or IHC, the signals localized mainly to the
alveolar epithelial cells, with lower intensity in alveolar
macrophages, indicating that the former are the chief target
cells of the virus. Only scattered positive cells were identified
in the bronchiolar epithelium, and no significant staining of
the bronchial epithelium was observed. No distinctive spread
to regional lymph nodes was seen, and we were not able to
determine colocalization with DC-SIGN–positive cells. Using
an oligonucleotide probe with signal amplification, Nakajima
et al. demonstrated SARS-CoV genomes in the alveolar
epithelium and macrophages of a 46-year-old woman with
SARS, but details of the clinical course of the disease were not
stated [19]. The preferential localization of the virus to
alveolar cell components relative to the bronchial epithelium
seen at the time of death suggests that the alveolar environ-
ment might be more permissive to viral replication, and
could also account for the high incidence of lower respiratory
tract involvement. It should be noted, however, that there are
no studies of SARS in humans in which bronchial or tracheal
biopsy material from nonfatal cases has been examined.
Therefore, whether there is SARS-CoV replication in these
parts of the respiratory tract, as is the case in nonhuman
primates [10], remains unanswered.
Among the 25 patients who died later than two weeks after
symptom onset, no ISH or IHC signals were detected in
postmortem lung tissues, even in lesions that were morpho-
logically earlier, such as alveolar edema and hyaline mem-
brane or in lungs showing heterogeneous morphological
Figure 1. Confirmation of the Specificity of the Monoclonal Antibody
4D11 for the SARS-CoV Nucleocapsid Protein
SARS-CoV immunohistochemical staining of 293T cells transfected with
spike (S), nucleocapsid (N), and spike, nucleocapsid, membrane, and
envelope (SEMN) genes of SARS-CoV. Untransfected control is shown in
the lower right photomicrograph. The monoclonal antibody 4D11
identifies the N protein. AEC stain with hematoxylin counterstain;
magnification 1003.
DOI: 10.1371/journal.pmed.0030027.g001
Figure 2. Examples of SARS-CoV IHC/ISH Results
No staining for N protein is present in the bronchus of HK case 1 (A), but
there is focal positive staining of bronchiolar epithelium in this case (B).
Positive staining is seen in epithelial cells and detached cells in the
alveoli in TO case 1 (C), which on higher magnification morphologically
resemble type 1 pneumocytes (D). In TO case 2, there is a thrombus
present which contains mononuclear and spindle-shaped cells (E).
Carbon-containing macrophages are also positive (F). Ten days after
symptom onset, positive staining was reduced and is noted mainly in the
exudates (G) with only very focal positive mononuclear cells seen (H).
AEC stain with hematoxylin counterstain; magnification 1003.
DOI: 10.1371/journal.pmed.0030027.g002
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progression, where relatively uninvolved areas were inter-
spersed among more advanced lesions.
These findings suggest that there is a decrease of SARS-
CoV replication and, consequently, a decrease in intracellular
viral copy numbers in lung tissue after the first two weeks of
disease, with the terminal event not dependent on continued
widespread viral replication. It has also been noted that viral
loads detected by RT-PCR or viral culture from nasophar-
yngeal aspirates, urine, and stool samples start to decrease
10–15 d after symptom onset, correlating with the time taken
for the development of specific anti-SARS antibodies, which
starts approximately 10 d from disease onset [5,20].
The identification of the cells infected by SARS-CoV in
humans has yielded contradictory findings. To et al., using
ISH combined with IHC, found dual labeling of only
epithelial cells using AE1/AE3 and negative staining for
macrophages (antibody CD68) [21]. In contrast, Chen and
Hsiao, using ISH, demonstrated a positive signal in carbon-
containing macrophages and also within vascular lumina [22].
A later report, also from Taiwan and using ISH, demon-
strated positive signal in pneumocytes and not in macro-
phages, but it is not clear if the same patient material (from a
36-year-old woman) was used in these last two publications
[23]. The discrepancies between these findings may be
partially explained by three factors: the choice of probes,
the age of the patient, and the disease progression. To et al.
[21] used the membrane (M) gene, whilst Chow et al. [23] used
a mixture of probes (N, M, and replicase [REP]) and found the
greatest intensity with the N and M gene and minimal
staining with the REP. Our findings support those of both To
et al. and Chow et al., in that there was mainly epithelial
staining but also definite macrophage (CD68) dual staining,
suggesting that, although epithelial cells are the main target
of SARS-CoV, the presence of viral RNA in macrophages
represents either phagocytosis or low-level replication in
these cells. None of these previous ISH-based studies have
demonstrated ISH-positive lymphocytes, as reported by Gu et
al. [24].
Our data also suggest that pneumocytes may be infected
first, followed by macrophages; TO case 1, who died 5 d after
symptom onset, had staining of pneumocytes but no other
cells, whereas all other cases, who died five or more days after
symptom onset had both pneumocyte and macrophage
staining. It is possible that the material used for the To et
al. study came from early cases. Shieh et al. describe finding
type 2 pneumocytes positive for SARS-CoV in one patient
[15]. However, in this study, staining appeared to be restricted
to morphological type 1 pneumocytes, in keeping with the
findings of Haagmans et al. [25]. However, Haagmans et al.
were unable to demonstrate macrophage uptake of SARS-
CoV [25]. We also found occasional bronchiolar epithelial
cells that were positive for SARS-CoV by ISH, IHC, and
electron microscopy, which has not been noted in other
studies. To this extent, the immunohistochemical findings are
similar to those seen with respiratory syncytial virus (RSV)
infections, in which there is staining of bronchial epithelial
cells, pneumocytes, and macrophages [26]. The age of the
patient is also important, as SARS has been associated with
greater mortality in the elderly than in the younger age
group, and laboratory studies have shown that ‘‘aged’’ mice
infected with SARS-CoV had more severe disease and greater
cytokine production than younger mice [27]. Thus, differ-
ences in age may also be responsible for some of the
differences noted between published results.
The spectrum of pulmonary lesions in the cases described
in this study is characteristic of the acute and resolving stages
of acute lung injuries, including DAD due to intrapulmonary
or extrapulmonary causes such as bacterial and viral
infection, trauma, shock, etc. Unlike the findings of Gu et
al., who demonstrated ISH-positive cells in giant cells [24], we
repeatedly found no evidence of positive staining by ISH or
IHC in the giant cells in our material. As giant cells were seen
mainly in patients after 14 d of disease duration, whether they
have the same mechanism of formation as seen in animal
models needs further investigation. Interestingly, multi-
nucleated epithelial cells have been noted in lung infections
due to other viruses such as measles, parainfluenza, and
respiratory syncytial viruses. In fact, none of the changes
observed in the present cases is unique for SARS-CoV
infection. The pathophysiological mechanisms underlying
DAD and subsequent pulmonary fibrosis have been inves-
tigated in clinical and experimental models [28,29]. It has
been shown that proinflammatory and fibrogenic cytokine
pathways are activated within the first 24–48 h following
pulmonary insult [30,31]. High initial levels of these activities
are associated with persistent pulmonary damage and
increased risks of subsequent pulmonary fibrosis and poor
outcome in DAD [32–34].
Previous studies have published viral loads per gram of
tissue using quantitative PCR. This quantitative PCR method
has been shown to be of value in determining viral load of
Figure 3. Colocalization of SARS-CoV Infection of Human Lung Tissues
Shown are tissue samples stained with SARS-CoV monoclonal nucleo-
capsid FITC and epithelial membrane antigen TRITC. At day 5 post-
infection, there is positive staining of type 1 pneumocytes (A), with
epithelial cell debris present in the alveolar lumen (B). In one case (TO
case 1), there is positive staining for SARS-CoV of the type 1
pneumocytes with no staining of CD68 positive macrophages (C and
D). HK case 1, however, shows FITC staining within the cytoplasm of
CD68-positive cells (E).
DOI: 10.1371/journal.pmed.0030027.g003
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viruses in peripheral blood, such as Epstein-Barr virus; but
unlike blood, lung tissue is not homogeneous and, in an
assessment of viral copies per gram of tissue, whether the
tissue sample contains bronchus, scar tissue, edema fluid, or
exudates is crucial. In addition, blood in tissues may lead to
false-positive PCR results due to viremia rather than viral
replication in the tissue. In this study, persons with high
SARS-CoV viral loads in their lung tissue had good
correlation with the IHC and ISH results [18], but lower lung
and organ tissue viral loads showed negative results. These
lower viral loads may reflect a small amount of residual
genome from a previous infection comparable to RSV
infections reported in both stable as well as acute exacer-
bation of chronic obstructive pulmonary disease patients [35].
This is a possible explanation for the low level of RT-PCR
positivity in the lung tissues and in other tissues in SARS
patients in which we could not detect SARS-CoV by IHC or
ISH. Furthermore, in the fatal cases of SARS most patients
had seroconverted at the time of death (unpublished data).
However, we cannot exclude the possibility of low-level
replication in these tissues that was not detectable by IHC
and ISH, due to possible limitations of the sensitivity of these
assays.
This study has shown that alveolar epithelium and macro-
phages are the chief targets of SARS-CoV infection in the
human lung, in agreement with the findings reported in a
primate model of the disease [10]. The predominant
infiltrating cell in the lungs were macrophages, and this
agrees with finding of high levels of macrophage-trophic
chemokines in vivo, and in response to SARS-CoV infection
in vitro [36]. However, the relative contributions of direct
viral damage versus immunopathology in the pathogenesis of
SARS remains unclear. Detectable levels of intracellular viral
RNA and proteins in lung tissue are present in only the
earliest phase of the disease, and they disappear by 2 wk after
the onset of symptoms. Although we found only four positive
cases by ISH and IHC, and all these were in patients who died
within the first 2-wk period, it is likely that many of the
negative postmortem cases would have been positive had a
lung biopsy been performed earlier. Lack of IHC and ISH
staining of extrapulmonary tissues in fatal cases of early SARS
suggest that viral involvement of major organs may not be as
widespread as data based on RT-PCR results have previously
suggested. Our findings have important implications on the
clinical and therapeutic management of SARS should it
return in the future, in that if antiviral therapy is to be
instituted, there may be a broader window of opportunity for
intervention with antiviral therapy than there is, for example,
with influenza, in which treatment within 48 h is required for
discernible clinical impact.
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Patient Summary
Background. The first SARS (severe acute respiratory syndrome)
outbreak started in November 2002 in China, and over the next five
months spread to a number of other cities around the world. During that
time, 20%–30% of the infected people became seriously ill, and 10%
died. SARS is caused by the SARS-CoV, which infects the lungs of patients
and leads to breathing problems. Since the outbreak, scientists around
the world have been working hard to understand the SARS virus and
how it causes disease, and to develop drug treatments and vaccines.
Why Was This Study Done? For this study, researchers from Hong Kong
and Toronto (both cities hit by the SARS outbreak) joined forces for a
large and detailed study of the bodies of patients who had died from
SARS. They hoped that this would help them to understand how the
virus had killed the patients, and when and how certain treatments
might be most effective. The researchers wanted to see whether there
were differences between individuals who died from SARS at different
times after they first fell ill. They were also interested in the distribution
of SARS-infected cells in the lungs of these patients, and whether they
could detect the SARS virus outside of the lung in other parts of the
body.
What Did the Researchers Do and Find? They studied the organs of 32
patients who had died from SARS. The researchers had detailed clinical
information on each of them. Some had died less than a week after they
became ill, and others had died after more than a month. The
researchers used a variety of modern scientific tools to visualize exactly
where in the bodies the SARS virus had reached. They detected the virus
in the lungs of most patients who died within two weeks of falling ill, but
not in the lungs of any of the patients who died after more than two
weeks of illness. Where detectable, the virus was mostly found in an area
of the lung called the alveolar epithelium. Each of your lungs is made up
of a network of breathing tubes, and each tube ends in a tiny pouch
called an alveolus, which is surrounded by blood vessels. When you
breathe in oxygen, it eventually passes into your bloodstream across the
lining of these pouches, and this lining is the alveolar epithelium. The
researchers also examined other organs (including heart, kidney, and
liver) from two of the patients whose lungs had tested positive for the
virus and three others who had shown no sign of virus in the lungs. They
did not detect the virus in any of these samples.
What Does This Mean? These results suggest that the SARS virus causes
illness and death by attacking cells in the alveolar epithelium. The virus
multiplies mostly within this group of cells, and only for a limited time
after infection. Antiviral drugs are likely to be only useful during this
initial time window after infection. After less than two weeks, the body’s
immune system seems to be able to fight back and prevent the virus
from further multiplying, but this does not lead to recovery in all
patients. In fact, most of the patients in this study (25 out of 32) died
more than two weeks after they became ill and without signs that the
SARS virus was still multiplying in their body. This suggests that in
patients who die, the initial damage to the lungs is so severe that they
cannot recover, and this is not dependent on continued virus replication.
The study also suggests that death from SARS is not due to the virus
multiplying outside of the lungs.
Where Can I Find More Information Online? The following Web sites
provide information on SARS.
Pages from the Government of Hong Kong:
http://www.info.gov.hk/info/sars/eindex.htm
Health Canada pages:
http://www.phac-aspc.gc.ca/sars-sras/index.html
Pages from the US Centers for Disease Control and Prevention:
http://www.cdc.gov/ncidod/sars/
World Health Organization pages:
http://www.who.int/csr/sars/en/
MedlinePlus pages:
http://www.nlm.nih.gov/medlineplus/severeacuterespiratorysyndrome.
html
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